Andrew A. Davis

Washington University in St. Louis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.

Year:

2025

Supplementary Table S1: Histology subtypes categorized as ILC, IBC-NST, or mixed. Supplementary Table S2. Representativeness of Study Participants Supplementary Table S3: All somatic P/LP short variants between ILC, IBC-NST, and mixed histologies occurring in ≥1% of either histology group. Supplementary Table S4: Copy number amplifications with q

Year:

2025

Purpose: Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, but distinct treatment strategies are limited. Better characterization of the genomic and transcriptomic landscape is critical to elucidate ILC tumor biology, improve histologic classification, and define precision medicine treatment approaches. Experimental Design: We retrospectively analyzed de-identified next-generation sequencing data of 4,613 metastatic patients from the Tempus database including 637 with ILC, 91 with mixed lobular/ductal histology, and 3,885 with invasive breast carcinoma of no special type (IBC-NST). Samples were profiled using the Tempus xT assays. Results: Mutations in CDH1 occurred in 71% of patients with ILC (453/637). The median tumor mutational burden was significantly higher in CDH1- mutant ILC samples compared with wild-type (WT) CDH1 samples ( P = 0.008). Mutations in PIK3CA (55% vs. 28%), ERBB2 (13% vs. 4.3%), and TBX3 (12% vs. 3.8%) were enriched in CDH1 -mutant ILC versus CDH1 -WT ILC. CDH1 expression was similar between CDH1- mutant ILC and CDH1 -WT ILC samples ( P = 0.11). Patients with CDH1- mutant mixed histology or IBC-NST had lower CDH1 expression than those with CDH1 -WT mixed histology or IBC-NST ( P P Conclusions: Our real-world data illustrate the distinct molecular landscape of CDH1- mutant metastatic ILC, and therapies targeting ERBB2 and PIK3CA should be further investigated in CDH1- mutant ILC. ILC differs from mixed and IBC-NST at a transcriptional level, suggesting the possibility of using CDH1 RNA expression levels to improve classification of ILC.

Year:

2025

Purpose: Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. Although molecular residual disease assays show promise, their use in the neoadjuvant setting requires rapid turnaround times. Tissue-informed approaches may be challenging for patients with limited biopsy samples. The objectives were to determine the surveillance sensitivity for detecting metastatic recurrence and evaluate the ctDNA response to neoadjuvant therapy (NAT) using a tissue-free epigenomic assay. Experimental Design: Patients with stage II or III TNBC undergoing neoadjuvant docetaxel and carboplatin chemotherapy on a clinical trial (NCT02124902) followed by surgery with or without adjuvant therapy were included in this study. Blood samples were prospectively collected before, during, and after completion of NAT and after surgery at prespecified surveillance time points. Plasma samples were analyzed by Guardant Reveal. Results: A total of 119 patients with TNBC were included in the analysis. ctDNA was detected in the postsurgical setting in 8.9% (7/79) of patients, with an 83% (5/6) patient-level surveillance sensitivity for metastatic recurrence and 99.5% (197/198) sample-level specificity. Postsurgical ctDNA detection was prognostic for the shorter recurrence-free interval (HR, 37.7; P P Conclusions: In patients with early-stage TNBC, a tissue-free, epigenomic assay demonstrated high specificity and sensitivity for metastatic recurrence. ctDNA detection in the neoadjuvant setting indicated poor prognosis, highlighting its potential role across breast cancer care.

Year:

2025

Purpose: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody–drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described. Experimental Design: We retrospectively analyzed 749 patients with metastatic breast cancer (MBC) and ctDNA evaluation by Guardant360 from three academic medical centers. Tumors were classified as HER2-low, HER2-0 (IHC 0) or HER2-positive. Single-nucleotide variants, copy-number variants, and oncogenic pathways were compared across the spectrum of HER2 expression. Overall survival (OS) was evaluated by HER2 status and according to oncogenic pathways. Results: Patients with HER2-low had higher rates of PIK3CA mutations [relative risk ratio (RRR), 1.57; P = 0.024] compared with HER2-0 MBC. There were no differences in ERBB2 alterations or oncogenic pathways between HER2-low and HER2-0 MBC. Patients with HER2-positive MBC had more ERBB2 alterations (RRR, 12.43; P = 0.002 for amplification; RRR, 3.22; P = 0.047 for mutations, in the hormone receptor–positive cohort), fewer ERS1 mutations (RRR, 0.458; P = 0.029), and fewer ER pathway alterations (RRR, 0.321; P P Conclusions: We observed a higher rate of PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between patients with HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.

Year:

2025

Introduction: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates (ADC). While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described. Materials and Methods: We retrospectively analyzed 749 patients with metastatic breast cancer (MBC) and ctDNA evaluation by Guardant360 TM from three academic medical centers. Tumors were classified as HER2-low, HER2-0 (IHC 0) or HER2-positive. Single nucleotide variants (SNVs), copy number variants (CNVs), and oncogenic pathways were compared across the spectrum of HER2 expression. Overall survival (OS) was evaluated by HER2 status and according to oncogenic pathways. Results: Patients with HER2-low had higher rates of PIK3CA mutations (RRR 1.57, P=0.024) compared to HER2-0 MBC. There were no differences in ERBB2 alterations or oncogenic pathways between HER2-low and HER2-0 MBC. Patients with HER2-positive MBC had more ERBB2 alterations (RRR 12.43, P=0.002 for amplification; RRR 3.22, P=0.047 for mutations, in the HR+ cohort), fewer ERS1 mutations (RRR 0.458, P=0.029) and fewer ER pathway alterations (RRR 0.321, P PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.

Year:

2024

Purpose: Early evaluation of tumor heterogeneity related to metastasis and outcomes is a major challenge in the management of advanced breast cancer (BCa) in the clinic. In this study, we introduced the value of baseline circulating tumor cells (CTC) and ctDNA for early differentiation of clinical stages, tumor heterogeneity, and prognosis in clinic. Experimental Design: A total of 292 patients with BCa were enrolled in this study, including 254 Stage IV and 38 Stage III patients, and examined the baseline levels of CTCs, CTC-clusters, and plasma ctDNA before initiating therapies. Outcomes including progression-free survival (PFS) and overall survival were evaluated using proportional hazards regression analysis. Results: The baseline CTCs, including HER2 + CTCs, in Stage IV patients were approximately 9.5 times higher than those detected in Stage III patients. Baseline CTC counts with a cutoff of 5 were significantly associated with the prognosis. Within each stage, patients with Conclusions: Assessing the baseline levels of CTCs, CTC-clusters, and mutational ctDNA profile could reliably aid in differentiation of clinical stage and early prediction of metastasis and outcomes in advanced BCa.

Year:

2024

Purpose: Early evaluation of tumor heterogeneity related to metastasis and outcomes is a major challenge in the management of advanced breast cancer (BCa) in the clinic. In this study, we introduced the value of baseline circulating tumor cells (CTC) and ctDNA for early differentiation of clinical stages, tumor heterogeneity, and prognosis in clinic. Experimental Design: A total of 292 patients with BCa were enrolled in this study, including 254 Stage IV and 38 Stage III patients, and examined the baseline levels of CTCs, CTC-clusters, and plasma ctDNA before initiating therapies. Outcomes including progression-free survival (PFS) and overall survival were evaluated using proportional hazards regression analysis. Results: The baseline CTCs, including HER2 + CTCs, in Stage IV patients were approximately 9.5 times higher than those detected in Stage III patients. Baseline CTC counts with a cutoff of 5 were significantly associated with the prognosis. Within each stage, patients with Conclusions: Assessing the baseline levels of CTCs, CTC-clusters, and mutational ctDNA profile could reliably aid in differentiation of clinical stage and early prediction of metastasis and outcomes in advanced BCa.

Year:

2024

Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.

Year:

2024

Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.

Year:

2024

Year:

2024

Year:

2023

Collaborators (15)

Carolina Reduzzi

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Ron Bose

Washington University School of Medicine

UNITED STATES
View details

PAVANKUMAR TANDRA

Assistant professor with a special interest in Breast Oncology

University of Nebraska Medical Center

UNITED STATES
View details

Foluso O. Ademuyiwa

-

UNITED STATES
View details

Mateusz Opyrchal

Associate Professor

Indiana University School of Medicine

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Jairam Krishnamurthy

Huntsman Cancer Institute

UNITED STATES
View details

Ian Hagemann

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Amir Behdad

-

UNITED STATES
View details

Rama Suresh

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Aditya Bardia

UCLA Health

UNITED STATES
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Lindsay L. Peterson

Washington University School of Medicine

UNITED STATES
View details

jingqin luo

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Akhil Chawla

Surgical Oncolgy

Northwestern Medicine

UNITED STATES
View details